A Phase 3 interventional study of Imatinib in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 7 sites in 7 countries. Per ClinicalTrials.gov, last updated 2015-08-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 9th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 6th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 15 more countries
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6
First in 2006; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 27 across the 12 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was an extension to study CQTI571A2102 and was to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in severe pulmonary arterial hypertension patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).
Drug: Imatinib
200 mg or 400 mg qd
Number of Patients With Adverse Events, Serious Adverse Events and Deaths
Adverse event monitoring was conducted throughout the trial.
Time frame: 144 weeks
Change From Baseline in the Six Minute Walk Distance (6MWD)
Time frame: baseline, 144 weeks
Time to Clinical Worsening (TTCW) Endpoints
Time frame: 144 weeks
Medical Resource Utilization
Time frame: 144 weeks
| Milestone | QTI571 |
|---|---|
| Started | 17 |
| Received 200 mg | 4 |
| Received 400 mg | 13 |
| Completed | 1 |
| Not completed | 16 |
| Withdrew: Death | 3 |
| Withdrew: Administrative problems | 8 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Adverse event | 3 |
Adverse event monitoring was conducted throughout the trial.
| Participants | QTI571 200 mg | QTI571 400 mg |
|---|---|---|
| Adverse Events (serious and non-serious) | 4 | 13 |
| Serious Adverse Events | 4 | 5 |
| Deaths | 2 | 1 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| QTI571 200mg | — | 4/4 (100%) | 4/4 (100%) |
| QTI571 400mg | — | 5/13 (38.5%) | 13/13 (100%) |
| Event | QTI571 200mg | QTI571 400mg |
|---|---|---|
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/4 | 0/13 |
| Right ventricular failureCardiac disorders | 1/4 | 0/13 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/4 | 1/13 |
| Inguinal herniaGastrointestinal disorders | 1/4 | 0/13 |
| BacteraemiaInfections and infestations | 1/4 | 0/13 |
| PeritonitisInfections and infestations | 1/4 | 0/13 |
| Septic shockInfections and infestations | 1/4 | 0/13 |
| Back painMusculoskeletal and connective tissue disorders | 1/4 | 1/13 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/4 | 0/13 |
| CatatoniaPsychiatric disorders | 1/4 | 0/13 |
| Event | QTI571 200mg | QTI571 400mg |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/4 | 3/13 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 6/13 |
| NasopharyngitisInfections and infestations | 0/4 | 6/13 |
| VomitingGastrointestinal disorders | 0/4 | 4/13 |
| LeukopeniaBlood and lymphatic system disorders | 1/4 | 0/13 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/4 | 0/13 |
| Abdominal discomfortGastrointestinal disorders | 1/4 | 1/13 |
| GastritisGastrointestinal disorders | 1/4 | 0/13 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/4 | 0/13 |
| ToothacheGastrointestinal disorders | 1/4 | 1/13 |
| Age, Continuous(Years) | QTI571 |
|---|---|
| Mean | 53.5 ± 14.3 |
| Sex: Female, Male(Participants) | QTI571 |
|---|---|
| Female | 11 |
| Male | 6 |
The record gives a start of Jun 2011, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib
Pulmonary Arterial Hypertension →